Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence
Current Oncology · 04.12.2023 · 30 (12) · 10311-10324
DOI: 10.3390/curroncol30120751 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Current Oncology, online erschienen am 04.12.2023. Verfasst von Jie Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Science and Technology Innovation Talent Project of Sichuan, China.
Abstract (Originalsprache)
Preclinical and clinical studies have suggested potential synergies of combining poly (ADP-ribose) polymerase (PARP) inhibitors and novel hormonal therapies (NHT) for patients with metastatic castration-resistant prostate cancer (mCRPC). We systematically searched PubMed, ClinicalTrials.gov and ASCO-GU annual meeting abstracts up to March 2023 to identify potential phase III trials reporting the use of combining PARP inhibitors with NHT in the first-line setting for mCRPC. A total of four phase III trials met the criteria for subsequent review. Emerging data suggested that the radiographic progression-free survival (rPFS) was significantly longer in the PARP inhibitor combined with NHT group versus the placebo plus NHT group for the first-line setting of biomarker-unselected mCRPC patients, especially for patients with homologous recombination repair (HRR) mutation (HRR m), and with the greatest benefit for BRCA1/2 mutation (BRCA1/2 m) populations. Final overall survival (OS) data of the PROpel trial indicated a significant improvement in median OS for mCRPC patients with HRR m and BRCA1/2 m receiving olaparib + abiraterone. Prior taxane-based chemotherapy might not influence the efficacy of the combination. Compared with the current standard-of-care therapies, combining NHT with PARP inhibitors could achieve a significant survival benefit in the first-line setting for mCRPC patients with HRR and BRCA1/2 mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Institute of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China.
ORCID-Profile: Qiang Wei
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Science and Technology Innovation Talent Project of Sichuan, China
- Clinical Research Incubation Project of West China Hospital of Sichuan University
Zitieren
APA
Yang, J., Xiong, X., Zheng, W., Liao, X., Xu, H., Yang, L., & Wei, Q. (2023). Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence. Current Oncology, 30(12), 10311-10324. https://doi.org/10.3390/curroncol30120751
Vancouver
Yang J, Xiong X, Zheng W, Liao X, Xu H, Yang L, et al. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence. Current Oncology. 2023;30(12):10311-10324. doi:10.3390/curroncol30120751
BibTeX
@article{Yang2023,
author = {Yang, Jie and Xiong, Xingyu and Zheng, Weitao and Liao, Xinyang and Xu, Hang and Yang, Lu and Wei, Qiang},
title = {Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {12},
pages = {10311--10324},
doi = {10.3390/curroncol30120751}
}
EUVIMED